Trial: 201909077

A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003)

Phase

III

Principal Investigator

Trikalinos, Nikolaos

Disease Site

Colon; Rectum

Learn more about this study at: clinicaltrials.gov